Growth Metrics

OmniAb (OABI) Gross Margin (2024 - 2026)

OmniAb (OABI) reported Gross Margin of 99.9% for Q1 2026, down 3.0% year-over-year from 102.99% in Q1 2025, and little changed on a QoQ basis from 99.89% in Q4 2025.

OmniAb (OABI) has 3 years of Gross Margin data on file, last reported at 99.9% in Q1 2026.

  • Quarterly Gross Margin fell 3.0% year-over-year to 99.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.91% (down 108.0% YoY) and the FY2025 annual result came in at 98.38%, down 162.0% from the prior year.
  • Gross Margin steadied at 99.9% in Q1 2026 per OABI's latest filing, from 99.89% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q2 2024 and bottomed at 93.28% in Q2 2025.
  • The 3-year median for Gross Margin is 99.91% (2025), against an average of 98.96%.
  • The widest annual swing landed in 2025, when Gross Margin slumped 672 bps; it then slipped 3 bps in 2026.
  • Tracing OABI's Gross Margin over 3 years: stood at 100.0% in 2024, then dropped by 0 bps to 99.89% in 2025, then climbed by 0 bps to 99.9% in 2026.
  • Per Business Quant, the three latest OABI Gross Margin figures stand at 99.9% (Q1 2026), 99.89% (Q4 2025), and 98.7% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 OmniAb 334.72 Mn 291.75 Mn 14.41 Mn 99.90%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 99.90%
Dec 31, 2025 99.89%
Sep 30, 2025 98.70%
Jun 30, 2025 93.28%
Mar 31, 2025 99.93%
Dec 31, 2024 100.00%
Sep 30, 2024 100.00%
Jun 30, 2024 100.00%